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Summary We have examined the expression of receptors for epidermal growth factor (EGFR) by the ZR-75-1 human breast cancer cell line and tamoxifen resistant and oestrogen independent/ tamoxifen sensitive (ZR-PR-LT) variants. The parent line expressed a single class of high affinity binding sites (4,340± 460 receptors/cell; Kd 0.23 + 0.04 nM). ZR-75-9a1 8 lM cells, routinely maintained in medium containing 8 ILM tamoxifen, were negative for oestrogen receptor (ER) and progesterone receptor (PGR) and expressed a markedly increased number of EGFR (14,723±2116 receptors/cell). Receptor affinity was unchanged. Time dependent reversal of the tamoxifen resistant phenotype was accompanied by a return to ER and PGR positivity and a fall in EGFR numbers to parent cell levels. In contrast ZR-PR-LT cells had a greatly reduced EGFR content (803 ± 161 receptors/cell) accompanying elevated PGR numbers. Pre-treatment of these cells with suramin or mild acid stripping failed to expose receptors which may have been occupied by endogenously produced ligand. Increased proliferation of ZR-75-1 cells treated with EGFR (0.01-10 ng ml ') was only observed in serum-free medium lacking insulin and oestradiol. Under these conditions untreated cells failed to proliferate. Both variant lines continued to proliferate in serum free medium in the absence or prescence of insulin and oestradiol but failed to respond to exogenous EGF.
It is now well established that breast cancer cell proliferation is influenced by several peptide growth factors acting in an autocrine or paracrine fashion. A number of studies have suggested that oestradiol may exert its growth promoting effect in part by stimulating the secretion of mitogenic peptides such as transforming growth factor (TGF) a (Dickson et al., 1986) and reducing the production of the inhibitory peptide TGFP whilst oestrogen independent breast tumours produce growth stimulatory peptides constitutively . TGFa functions through interaction with the epidermal growth factor receptor [EGFR] (Derynck, 1988) and EGF itself is also a potent mitogen for breast cancer.
EGFR is the cellular homologue of the product of the c-erbB oncogene and its presence in primary breast tumours is a strong prognostic factor. Patients presenting with tumours positive for EGFR tend to be oestrogen receptor (ER) negative and have an increased risk of early recurrence and death (Sainsbury et al., 1987) . Such patients are also at risk of rapid disease progression in the face of antioestrogen therapy (Nicholson et al., 1988a) . Whilst it may be postulated that elevated EGFR expression may sensitise cells to the mitogenic effects of EGF and/or TGFx there is a poor correlation between EGFR levels and response to EGF. Cell lines in vitro expressing high EGFR numbers are generally growth inhibited by EGF (Barnes, 1982; Filmus et al., 1985) and it has been suggested that EGFR may be upregulated by agents such as progestins which are in themselves growth inhibitory (Murphy et al., 1985) . Elucidation of the relationship between EGFR expression by breast carcinoma cells in vitro and response to EGF/TGFa is further complicated by the marked influence of culture conditions on response (Osborne et al., 1980; Nelson et al., 1989) Fibro- nectin (100 ng ml'), , Insulin (5 x 10-7M) and oestradiol (10-8M). Cell proliferative capacity and response to EGF was also assessed on cells growing in SFM lacking insulin or oestradiol.
Radioiodination of EGF EGF was radioiodinated using the lodogen method (Fraker & Speck, 1978) . EGF (10 fg) in 100 ll of 0.2 M sodium phosphate buffer, pH 7.4, was added to an Iodogenr (41ig) coated tube followed by 37 MBq NaT'25. The reaction proceeded for 20 min at 25°C and the mixture fractionated by reverse-phase high-performance liquid chromatography (HPLC) using a Waters Associates (Milford) gradient system fitted with an analytical it-Bondapak C18 column. The eluting gradient was Trifluoroacetic acid [TFA]/Water (0.05%/ 99.5% v/v) to TFA/Water/Acetonitrile (0.05/29.95/70.0 v/v) at a flow rate of 1.5 ml min-. The column eluent was monitored at 214 nm (AUFS 0.2) and fractions were collected every 30s (0.75 ml). Twenty-five tlI aliquots from each fraction were taken for monitoring of radioactivity and peak fractions were pooled and stored in aliquots containing 4% FCS. The specific activity of 1251 EGF prepared on five occasions using this method ranged from
Receptor assays Oestrogen receptor (ER) and progesterone receptor (PGR) expression was determined using a whole cell binding assay at 37°C as previously described (van den Berg et al., 1987) . For EGFR assays cells (2 x 105) were plated into 24 place multiwell dishes. Cells were allowed to attach for either 24 or 48 h in drug-free medium and 1251 EGF binding was then assessed at 4°C. Medium was replaced with RPMI medium (0.5 ml) supplemented with 1% bovine serum albumin containing 1251I EGF (0.2-4 nM) in the absence or presence of a 100-fold excess of non-labelled EGF to determine nonspecific binding. Following a 1 h incubation period medium was removed and wells were rinsed twice with ice-cold PBS.
1 M NaOH (500 JLl) was added to each well and plates were incubated for 1 h at 37°C to extract radioactivity. Extracts were removed by aspiration and wells were washed once with the same volume of alkali. Washings were added to the appropriate tubes and radioactivity determined by gamma counting (NEN 1600) or scintillation counting (LKB Wallac 1410 LSC). Since it has been shown that pretreatment of cells with the polyanionic drug suramin can reveal EGFR occupied by endogenously produced TGFax (Coffey et al., 1987; Clarke et al., 1989) in certain experiments ZR-PR-LT cells were exposed to suramin (1 mg ml 1) for 24 h prior to EGFR measurement. As an alternative method, PBS rinsed cells were subjected to mild acid stripping (2 x 3 min treatments with 1 ml 0.05 M sodium acetate buffer, pH 4.5, containing 150 mM NaCl) prior to EGFR assay. Maximum binding capacity (Bmax) and affinity (Kd) were calculated by Woolf analysis after linearisation of specific binding data (Keightly & Cressie, 1980) .
Effects of EGF on cell proliferation
Cells (5 x 104 per well) were plated into 24 place multiwell dishes in routine growth medium. After a 24 h attachment period medium was replaced with medium containing EGF (0.01-10 ng ml-') and cells were counted at 0, 6 and 9 days during continuous treatment using a Coulter Counter Model D. In experiments to determine the effect of EGF on cell proliferation in SFM, plating medium was replaced with SFM or SFM lacking insulin and oestradiol and cells allowed to adapt to growth under these conditions for 2 days before exposing them to EGF. (Keightly & Cressie, 1980 ) revealed a single class of high affinity binding sites (Figure 1 inset) . Figure 2 shows the marked differences in specific binding of 1251I EGF to the three cell lines under investigation. Table II shows mean values of three determinations of EGFR expression (Bmax, expressed as receptor number per cell) and affinity of (Table II) .
Results
If the tamoxifen resistant line is transferred to drug and phenol red free medium supplemented with 5% FCSdcc the ER and PGR negative phenotype is maintained for at least 12 weeks (van den Berg et al., 1989) . Table III shows that under these culture conditions EGFR receptor expression over a 4 week period remained elevated in comparison to parent line values. However, ZR-75-9al cells maintained long-term in the absence of drug or oestrogenic activity express both ER and PGR (Table I ) and are growth inhibited by tamoxifen (data not shown). Table III shows that EGFR expression by these cells had fallen to a value similar to that of the parent line.
None of the cell lines under study responded to exogenous EGF when grown under routine culture conditions (data not shown). Figure 3 compares the proliferation of the cell lines under these conditions with their proliferative rate in SFM and SFM lacking insulin and oestradiol. All cell lines grew more slowly in SFM than in the presence of FCS or FCSdcc. Values represent means ± standard errors of three determinations.
In the absence of insulin and oestradiol (Clarke et al., 1989; Nicholson et al., 1988b) . Had these low affinity receptors been present in the cell lines under study it is likely that biphasic Woolf plot would have been generated since the ligand concentration range used should have detected such binding sites. However we cannot discount the possibility that a second class of binding sites with a substantially lower affinity for EGF may be expressed by these cells. High affinity EGFR numbers expressed by ZR-75-1 cells in this study (Table II) viously published data for this cell line (Davidson et al., 1987) . Both variant lines expressed markedly altered EGFR numbers (Table II) . It has been shown that patients presenting with breast tumours positive for EGFR tend to be ER negative, have a poor prognosis and are resistant to tamoxifen treatment (Sainsbury et al., 1987; Nicholson et al., 1988a) . This inverse relationship between EGFR and ER expression has been confirmed using a panel of human breast cancer cell lines (Davidson et al., 1987) . Our data suggest that acquired tamoxifen resistance as exemplified by the ZR-75-9al 8 JiM cell line may also be associated with an increase in EGFR numbers without a change in receptor affinity (Figure 2 and Table II ) accompanying loss of ER and PGR. Furthermore, time dependent reversal of the tamoxifen resistant phenotype is also accompanied by a fall in EGFR numbers and a return to ER and PGR positivity (Tables I  and III) . These findings add further support to the proposal that there is an inverse relationship between EGFR and ER expression and that a mechanism of hetero-specific receptor modulation exists. In contrast to our results with the tamoxifen resistant variant, the oestrogen independent/tamoxifen sensitive line ZR-PR-LT expresses a markedly depressed number of EGFR. This does not seem to be the result of partial receptor occupation or down-regulation by endogenously produced ligand as suramin pre-treatment or acid washing failed to reveal additional binding sites. The ZR-PR-LT line is unusual in that although it appears to be negative for Type 1 ER on ligand binding analysis it expresses very high levels of PGR in the absence of any oestrogenic activity (van den Berg et al., 1990 and Table I ). The mechanism(s) responsible for this phenotype remain unclear but may involve a mutant ER lacking the ligand binding site, but active in the absence of ligand (Graham et al., 1990) or multiple copies of the PGR gene (Savouret et al., 1991) . Whatever the mechanism, our results with both ZR-75-9al 8 JAM and ZR-PR-LT cells suggest that there may also be an inverse relationship between PGR expression and EGFR content. In support of this hypothesis oestradiol, which normally induces PGR synthesis, has been reported to downregulate EGFR in MCF-7 cells (Berthois et al., 1989) . It may also be relevant that short term oestrogen withdrawal which markedly reduces PGR expression (van den Berg et al., 1990) results in elevated expression by MCF-7 and T47-D cells of the c-erbB-2 oncogene and its encoded p185 protein, a close EGFR homologue, whilst expression is repressed following oestrogen treatment (Dati et al., 1990) .
Our data on EGFR numbers in these variants of the ZR-75-1 line contrast with an earlier report from this laboratory which showed no significant changes in expression of receptors for Interferon a 2c (Martin et al., 1991 (Zoon et al., 1986; Hamburger & Pinnamaneni, 1991) .
The relationship between EGFR expression and proliferative response to ligand is unclear, but several studies have suggested that elevated EGFR expression is associated with growth inhibition rather than growth stimulation (Barnes et al., 1982; Filmus et al., 1985) although this relationship is by no means clear cut (Rizzino et al., 1988) and evidence has been presented to suggest that growth inhibition in vitro may be artifactual (Ginsburg & Vonderhaar, 1985) . We have confirmed that ZR-75-1 cells respond to EGF with growth stimulation, but we were only able to demonstrate a consistent response when cells were cultured in SFM lacking the potent mitogens insulin and oestradiol (Figure 4) . The reasons for these findings are unclear but several studies have demonstrated that culture conditions can markedly infuence response to EGF (Osborne et al., 1980; Nelson et al., 1989) .
It is also possible, as early studies suggested (Barnes et al., 1982) , that EGF and insulin may share a common pathway distal to receptor-ligand interaction. In the absence of EGF ZR-75-1 cells failed to proliferate in SFM lacking insulin and oestradiol whilst ZR-75-9al 8 JM and ZR-PR-LT cells proliferate at a rate only marginally slower than in SFM containing these mitogens (Figure 3) and EGF was without effect in the absence or presence of insulin and oestradiol. The ability of the tamoxifen resistant and oestrogen independent variants to proliferate in SFM lacking insulin or oestradiol would be consistent with the secretion by these cells of growth factors acting in an autocrine fashion (Dickson et al., 1986) . Additional studies are underway to test this hypothesis but the failure of ZR-PR-LT cells to express increased EGFR numbers following suramin treatment or acid washing (Table II) is not consistent with occupation of receptor by TGFa. The failure of this line to respond to EGF may therefore be simply due to the very low number of receptors for EGF expressed. In contrast the tamoxifen resistant variant expresses an elevated number of receptors but also fails to respond to EGF. The reason for this is currently unknown. Whilst a number of reports have suggested that cell lines expressing elevated numbers of EGFR are either growth inhibited by or fail to respond to EGF (Barnes et al., 1982; Filmus et al., 1985; Davidson et al., 1987) these cell lines express EGFR numbers at least one order of magnitude higher than those reported in this study for ZR-75-9a1 8 JAM cells.
Since neither of the variant lines used in this study are clonal in origin we are unable to say whether cells of their phenotype were selected from the parent line population or arose as a result of phenotypic alteration. Double labelling immunohistochemistry experiments would be of value in determining whether heterogeneity exists within cell populations or whether, for example, a pre-existing population of high EGFR/low ER cells is being selected for by prolonged tamoxifen exposure.
In summary, our results with the tamoxifen resistant line are in agreement with those of earlier studies which have indicated an inverse relationship between ER and EGFR content of breast cancer cells and further indicate that acquired tamoxifen resistance may also be associated with elevated EGFR numbers and that reversal of the resistant phenotype results in a fall in EGFR expression. Our data also suggest that the acquisition of oestrogen insensitivity associated with elevated PGR expression, as exemplified by ZR-PR-LT cells, may have opposite effects on EGFR numbers. Further studies will be required to test the genera-I lity of our findings but these and earlier studies indicate that there is a complex relationship between expression of receptors for factors influencing the proliferation of breast cancer cells, response to those factors and their role in the development of hormonal independence.
